



Association of Alanine Aminotransferase With Different Metabolic Phenotypes of Obesity in Children and Adolescents: The CASPIAN-V Study

OPEN ACCESS

Edited by:

Eli Hershkovitz,
Soroka Medical Center, Israel

Reviewed by:

Anastasia Ibba,
Ospedale Pediatrico Microciternico
"A. Cao", Italy
Gianluca Tornese,
IRCCS Materno Infantile Burlo
Garofolo (IRCCS), Italy

*Correspondence:

Mostafa Qorbani
mqorbani1379@yahoo.com
Ramin Heshmat
raminheshmat@tums.ac.ir

Specialty section:

This article was submitted to
Pediatric Endocrinology,
a section of the journal
Frontiers in Endocrinology

Received: 28 October 2019

Accepted: 07 May 2020

Published: 07 August 2020

Citation:

Kelishadi R, Hemati Z, Qorbani M,
Motlagh ME, Djalalinia S, Ahadi Z,
Shafiee G, Mahdavi Gorabi A,
Rastad H, Ziaodini H, Daniali SS and
Heshmat R (2020) Association of
Alanine Aminotransferase With
Different Metabolic Phenotypes of
Obesity in Children and Adolescents:
The CASPIAN-V Study.
Front. Endocrinol. 11:358.
doi: 10.3389/fendo.2020.00358

Roya Kelishadi¹, Zeinab Hemati¹, Mostafa Qorbani^{2,3*}, Mohammad Esmaeil Motlagh⁴, Shirin Djalalinia⁵, Zeinab Ahadi⁶, Gita Shafiee⁶, Armita Mahdavi Gorabi⁶, Hadith Rastad⁷, Hasan Ziaodini⁸, Seyede Shahrbanoo Daniali¹ and Ramin Heshmat^{6*}

¹ Pediatrics Department, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran, ² Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran, ³ Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁴ Pediatrics Department, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, ⁵ Development of Research and Technology Center, Deputy of Research and Technology, Ministry of Health and Medical Education, Tehran, Iran, ⁶ Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁷ Social Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran, ⁸ Bureau of Health and Fitness, Ministry of Education and Training, Tehran, Iran

Aim: To determine the association of alanine aminotransferase with different metabolic phenotypes of obesity in a nationally- representative sample of Iranian children and adolescents.

Methods: This national study was conducted in the framework of the fifth survey of a national surveillance program entitled Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease study. Participants consisted of 4,200 subjects aged 7–18 years, who were recruited by multistage random cluster sampling from 30 provinces in Iran. They were categorized to normal weight and obese groups and in each group those with and without MetS components.

Results: Overall, 3,843 of participants completed the survey (response rate: 91.5%). Their mean (SD) age was 12.58 (3.15) years; 52.6% were boys, and 72.7% lived in urban areas. Mean of alanine aminotransferase (ALT) in subjects with abdominal obesity and general obesity was 8.81 (95% CI: 7.99–9.62) (IU/L) and 8.87 (95% CI: 7.28–10.46) (IU/L), respectively. According to the adjusted model, one unit increment in ALT increased odds of being metabolically non-healthy obese (MNHO) by 2% compared to metabolically healthy non-obese (MHNO) [adj.OR (95% CI): 1.02 (1.01–1.04)]. Also, subjects in the

third and fourth quartiles of serum ALT had significantly greater odds of being MNHO than those in its first quartile [Q3/Q1: adj. OR (95% CI): 3.85 (1.70–8.71); Q4/Q1: Adj. OR (95% CI): 3.63 (1.51–8.73)].

Conclusion: This large population-based study revealed significant associations between metabolic phenotypes of obesity and ALT level.

Keywords: alanine aminotransferase, obesity, metabolic syndrome, children and adolescents, Iran

INTRODUCTION

Childhood obesity and metabolic syndrome (MetS) has become a worldwide problem and is no longer only limited to high-income countries (1, 2).

Serum alanine aminotransferase (ALT) is the liver enzyme most strongly correlated with liver fat accumulation (3), a surrogate marker for non-alcoholic fatty liver disease (NAFLD) (4). Besides, obese children with modest elevations of ALT might present metabolic impairment including deterioration in insulin sensitivity and glucose tolerance, hypertriglyceridemia, and hypoadiponectinemia (5).

While a large number of studies showed the association of liver enzymes with cardio-metabolic components and metabolic syndrome (6, 7), a few studies have examined the association of these enzymes with the different metabolic phenotypes of obesity, especially in children and adolescents (8–10). Therefore, this study aims to determine the association of ALT level with different metabolic phenotypes of obesity in children and adolescents.

METHODS

The present study was a part of “the fifth survey of the school-based surveillance system entitled Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease (CASPIAN-V) study” (2014-2015) conducted in 30 provinces of Iran. Details on the study protocol have been discussed previously (11), and we briefly point to the main parts.

Study Population and Sampling

Using the multistage stratified cluster sampling method, the study participants were selected from 7 to 18-year-old school subjects living in urban and rural areas of 30 provinces.

In each province, proportional to the size sampling method which was adopted to obtain a representative sample of students from rural/urban area and from primary/secondary school grades, with an equal sex ratio (12).

Achieving the desired number of samples was obtained using cluster sampling in each province with equal cluster sizes. Clusters were determined at school levels. The size of each cluster was 10 subjects; meaning that a total of 10 statistical units (including 10 subjects and their parents) would be considered in each cluster. The sample size of the main survey included 480 subjects in each province (48 clusters of 10 subjects), i.e., a total of 14,400 subjects at the national level. In each province, 14 out of 48

clusters were randomly selected for biochemical tests. Therefore, the sample size of the current study was estimated to be 4,200.

Procedure and Measurements of Data

Gathering

Demographic Information

Through an interview with parents or child, demographic information was asked for all subjects in the sampled classes of the selected schools. Family-based characteristics including family history of chronic diseases (hypertension, dyslipidemia, diabetes, and obesity), parental level of education (the highest total years of schooling), possessing a family private car and the type of home (rented/owned), dietary behaviors, physical activity (PA), and sedentary lifestyle were all considered.

Questionnaires

Data for subjects gathered through the Persian-translated version of the questionnaire was developed based on the World Health Organization-Global School Student Health Survey (WHO-GSHS) (13). The validity and reliability of questionnaires have been assessed through previous assessments (14).

Moreover, demographic information including age, sex, family history of diseases and metabolic risk factors, complementary data on family characteristics, namely household size, the birth order of subjects, and socioeconomic variables were questioned through parents' questionnaires.

Measurements

Under standard protocols and by using calibrated instruments, a team of trained health care experts performed the physical examination. Weight was measured in light clothing to the nearest 0.1 kg on a SECA digital weighing scale (SECA, Germany). Height was assessed without shoes to the nearest 0.1 cm while the subjects were standing, and the shoulders were in normal position (13).

We calculated Body mass index (BMI) by dividing weight (kg) to height squared (m^2) and categorized it using the WHO growth charts (13).

We measured waist circumference (WC) using a non-elastic tape at a point midway between the lower border of the rib cage and the iliac crest at the end of normal expiration to the nearest 0.1 cm. We also measured Hip circumference at the widest part of the hip at the level of the greater trochanter to the nearest 0.1 cm.

Blood pressure was measured in the sitting position on the right arm using a mercury sphygmomanometer with an appropriate cuff size. It was measured two times at 5-min

intervals; systolic and diastolic pressures were recorded and the average was registered (15).

Physical activity (PA): Through a validated questionnaire, information of weekly frequency of leisure time PA outside the school was collected, for the previous week (14). In this regard; at least 30 min duration of exercises per day, that caused heavy sweating or large increases in breathing or heart rate, was defined as PA. The response options were categorized as; none, 1–2 days, 3–6 days, and every day. For statistical analysis, each weekly frequency categorized into two groups; 0–3 days per week (Low); 4–7 days (High) (16).

Screen time (ST): The ST behavior of the children was assessed through the questionnaire that asked them to report the average number of hours/days they spent on watching Television (TV)/Video compact discs (VCDs), personal computer (PC), or electronic games (EG) in time of weekdays and weekends.

Socioeconomic status (SES): For assessment of the subjects' SES, we used principal component analysis (PCA) method by including questions related to parental education, parents' job, possessing a private car, school type (public/private), and having a personal computer which were combined as a unique index (11).

Laboratory Analysis

Selected subjects for blood sampling were referred to the predefined laboratory. After a 12-h overnight fasting 6 mL venous blood sample was collected. All collection tubes were centrifuged at $2500\text{--}3000 \times g$ for 10 min. Immediately after centrifugation, serum samples were aliquot into 200 microliter tubes and stored at -70°C . Using a comprehensive by cold chain program, all of the samples were transferred to Isfahan Mahdiah Laboratory. Alanine aminotransferase (ALT), Fasting blood glucose (FBG), triglycerides (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C) were measured enzymatically by Hitachi auto-analyzer (Tokyo, Japan) (17, 18).

Definitions

Metabolic syndrome (MetS) and its indicators

We used the Adult Treatment Panel III (ATP III) criteria modified for children and adolescents; participants were considered as having MetS if they met at least three of the five cardiometabolic risk factors: abdominal obesity, elevated BP, elevated FBG, high serum TG, and low serum HDL (19, 20). We defined these five cardiometabolic risk factors as below:

Abdominal obesity: waist-to-height ratio ≥ 0.5 ; elevated BP: BP $\geq 90^{\text{th}}$ percentile, elevated FBG: FBG ≥ 100 mg/dL, high serum TG: Serum TG ≥ 100 mg/dL; and low serum HDL: HDL-C ≤ 40 mg/dL.

Obesity

We used the WHO growth curves to define BMI categories, (13), i.e., age and sex-specific BMI in the 85th to 95th percentile was considered overweight, and age and sex-specific BMI $\geq 95^{\text{th}}$ percentile as obesity.

Also, according to the BMI status, our participants fall into four different phenotypes of obesity groups:

- Normal: 5th < BMI < 85th percentile and waist-to-height ratio (WHtR) < 0.5,
- Only abdominal obesity: WHtR > 0.5 and BMI < 95th percentile,
- Only general obesity: BMI > 95th and WHtR < 0.5,
- Combined obesity: BMI > 95th and WHtR > 0.5.

Metabolic phenotypes of obesity

Participants were classified into four groups according to their obesity and metabolic syndrome status:

1. Metabolically Healthy Obese (MHO): Obese individuals without metabolic syndrome.
2. Metabolically non-healthy Non-Obese (MNHNO): Non-obese individuals with metabolic syndrome.
3. Metabolically Non-healthy Obese (MNH): Obese individuals with metabolic syndrome.
4. Metabolically Healthy Non-Obese (MHNO): Non-obese individuals without metabolic syndrome.

Ethical Concerns

The Research and Ethics council of Isfahan University of Medical Sciences reviewed and approved the Study protocol (Project number: 194049). After a complete explanation of the study objectives and protocols, written informed consent was obtained from the parents of participants older than 16 years old in this study, while oral consent was obtained from the participants under 16 years.

Statistical Analysis

Using STATA package ver. 11.0 (Stata Statistical Software: Release 11. College Station, TX: Stata Corp LP. Package). All statistical measures were estimated using survey data analysis methods. We summarized continuous variables by mean and standard deviation (SD), and categorical variables by number (percentage).

Mean of ALT between different phenotypes of obesity and metabolic syndrome was compared by analysis of variance (ANOVA) and Tukey *post hoc* test.

The association of ALT with different (metabolic) phenotypes of obesity was assessed using crude and adjusted multinomial regression models. To perform regression analysis, serum ALT levels were also divided into four quartiles (Q) (Q1: ≤ 5 IU/L [$n = 1,093$], Q2: 6-7 IU/L [$n = 983$], Q3: 8-10 IU/L [$n = 968$], Q4: ≥ 11 IU/L [$n = 799$]). We reported crude and adjusted ORs for the second, third, and fourth quartiles of ALT levels compared to its first quartile.

In the adjusted model, the association was adjusted for age, gender, ST, PA, SES, and living area. Results of multinomial logistic regression presented as odds ratio (OR) and 95% confidence interval (CI). *P*-value of < 0.05 was considered as statistically significant.

RESULTS

From the 4,200 invited subjects, 3,843 participants completed the survey (response rate: 91.5%). Their mean (SD) age was 12.58 (3.15) years; 52.6% were boys, and 72.7% lived in urban areas.

TABLE 1 | Mean (95% CI) of Alanine aminotransferase (ALT) according to the different phenotypes of obesity regardless of MetS status: the CASPIAN-V study.

Groups	ALT (IU/L)		
	Mean	95% CI	P-value
Normal ^a	8.19	7.95–8.45	0.11
Only abdominal obesity ^b	8.81	7.99–9.62	
Only general obesity ^c	8.87	7.28–10.46	
Combined obesity ^d	8.94	8.29–9.59	

^aNormal: 5th < BMI < 85th percentile and WHtR < 0.5.

^bOnly Abdominal obesity: WHtR > 0.5 and BMI < 95th percentile.

^cOnly Generalized obesity: BMI > 95th and WHtR < 0.5.

^dCombined Obesity: BMI > 95th and WHtR > 0.5.

*P ≤ 0.05 is considered as significant.

ALT, Alanine aminotransferase; CI, confidence interval.

TABLE 2 | Mean (95% CI) of Alanine aminotransferase (ALT) according to the different metabolic phenotypes of obesity: the CASPIAN-V study.

Groups	ALT (IU/L)			
	Mean	95% CI	P-value between groups	P-value within groups
MHNO ^a	8.27	8.02–8.52	0.002	0.98 ^{ab}
MHO ^b	8.41	7.81–9.01		0.90 ^{bc}
MNHNO ^c	8.72	7.70–9.74		0.001 ^{ad}
MNHO ^d	11.58	9.33–13.84		0.97 ^{bc}
				0.005 ^{bd}
				0.042 ^{cd}

^aMHNO, Metabolic Healthy Non Obese (healthy).

^bMHO, Metabolic Healthy Obese.

^cMNHNO, Metabolic Non Healthy Non Obese.

^dMNHO, Metabolic Non Healthy Obese.

*P ≤ 0.05 is considered as significant.

ALT, Alanine aminotransferase, CI, confidence interval.

The mean of ALT in subjects with abdominal obesity and general obesity was 8.81 (95% CI: 7.99–9.62) (IU/L) and 8.87 (95% CI: 7.28–10.46) (IU/L), respectively. As presented in **Table 1**, the mean level of ALT had no statistical difference across various phenotypes of obesity (P = 0.11).

Table 2 shows that the mean level of ALT was significantly different across the metabolic phenotypes of obesity (P = 0.002). Results of the *post hoc* test showed that the mean level of ALT was higher in the MNHO group compared to the MHNO, MHO, and MNHNO groups (P < 0.05).

The association of ALT concentration with different obesity phenotypes in multinomial regression models is presented in **Table 3**. Overall, it shows no significant association between the ALT concentration and the different phenotypes of obesity (general and abdominal obesity) in crude and adjusted models.

Table 4 presents the association of ALT with different metabolic phenotypes of obesity in multinomial regression models. According to the adjusted model, one unit increment in ALT increased odds of being MNHO

(compared to MHNO) by 2% [Adj. OR (95% CI): 1.02 (1.01–1.04)].

Adjusted multinomial regression analysis also demonstrated that subjects in the third and fourth quartiles of ALT level compared to those in its first quartile were more likely to be MNHO [Q3/Q1: Adj.OR (95% CI): 3.85 (1.70–8.71); Q4/Q1: Adj.OR (95% CI): 3.63 (1.51–8.73)].

DISCUSSION

We found that the MNHO group has a higher mean ALT level compared to MHNO and MHO groups. According to the results from adjusted multinomial regression models, one unit increment in ALT increased odds of being MNHO (compared to MHNO) by 2% independent of age, gender, physical activity, screen time, socioeconomic status, and living area. However, we did not detect any significant association between ALT level with different forms of obesity (only abdominal obesity, only general obesity, and combined obesity) regardless of the MetS status.

In line with our study, Aldhoon-Hainerová et al. found that alanine aminotransferase could differentiate MNHO from Metabolically Health without abdominal obesity in both sexes in adolescence and from Metabolically Health regardless of waist circumference obesity in boys (8). Likewise, Suárez-Ortegón et al. observed a higher serum ALT level in children with MNHO (vs. MHO), and metabolically unhealthy overweight (vs. metabolically healthy overweight) (9). Xie et al. in a cross-sectional study on 2,197 obese (BMI ≥ 25 kg/m²) adults older than 40 years observed that the ALT might be an effective marker for identifying MNHO in this population (10).

Besides, in a study in children and adolescents, those with hypertriglyceridemic-waist phenotype had a higher level of ALT than those without this phenotype (21).

Individuals with MNHO have an increased level of liver enzymes and are at increased risk for hepatic steatosis (22, 23).

Higher levels of liver enzymes, especially ALT, may indicate higher liver fat deposition. Liver fat is a useful tool to assess metabolic health status (24).

We did not find significant differences between MHO and MNHNO with MHNO regarding the ALT serum level. Some other studies also documented that MHO individuals have lower levels of ectopic liver fat and potentially lower risk of NAFLD (25, 26).

In contrast, a study reported that the prevalence of NAFLD was similar in MHO and overweight participants, but higher than those with normal weight (26). On the other hand, the concept of MNHNO is of concern both in adults and in pediatric populations (27, 28). However, some obese individuals have no metabolic impairment it should be considered that the MHO individuals are not healthy, and in spite of their normal metabolic profile, they might face other adverse health effects of obesity (29). These individuals are a high-risk group for insulin resistance, cardiovascular risk diseases, and related mortality (30, 31).

TABLE 3 | Association of Alanine aminotransferase (ALT) with different phenotypes of obesity regardless of the MetS status in multinomial logistic regression models: the CASPIAN- V study.

Group /variable		Only abdominal obesity ^a		Only general obesity ^b		Combined Obesity ^c	
		Model I ^d	Model II ^e	Model I ^d	Model II ^e	Model I ^d	Model II ^e
		Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
ALT (Quartiles)	Q2/Q1	0.97 (0.74–1.29)	1.03 (0.76–1.39)	1.00 (0.59–1.69)	1.03 (0.58–1.80)	1.01 (0.72–1.41)	1.05 (0.73–1.51)
	Q3/Q1	1.19 (0.91–1.56)	1.24 (0.93–1.66)	0.71 (0.39–1.26)	0.75 (0.41–1.39)	1.26 (0.91–1.74)	1.21 (0.85–1.72)
	Q4/Q1	1.09 (0.82–1.46)	1.15 (0.85–1.57)	1.05 (0.60–1.81)	1.02 (0.56–1.86)	1.41 (1.01–1.96)*	1.28 (0.89–1.83)
ALT (IU/L)		1.01 (0.99–1.02)	1.00 (0.99–1.02)	1.01 (0.99–1.03)	1.01 (0.99–1.03)	1.01 (0.99–1.02)	1.01 (0.99–1.02)

^aOnly Abdominal obesity: WHtR>0.5 and BMI < 95th percentile.

^bOnly Generalized obesity: BMI>95th and WHtR<0.5.

^cCombined Obesity: BMI>95th and WHtR>0.5.

^dCrude model.

*p < 0.05.

^eAdjusted for age, gender, physical activity, screen time, socioeconomic status, and living area.

ALT, Alanine aminotransferase; OR, odds ratio CI: confidence interval.

ALT Quartiles: Q1: ≤ 5 IU/L [n = 1,093], Q2: 6-7 IU/L [n = 983], Q3: 8-10 IU/L [n = 968], Q4: ≥ 11 IU/L [n = 799].

TABLE 4 | Association of Alanine aminotransferase (ALT) with different metabolic phenotypes of obesity in multinomial logistic regression models: the CASPIAN- V study.

Group /variable		MHO ^a		MNHNO ^b		MNHO ^c	
		Model I ^d	Model II ^e	Model I ^d	Model II ^e	Model I ^d	Model II ^e
		Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)	Crude OR (95% CI)	Adjusted OR (95% CI)
ALT (Quartiles)	Q2/Q1	0.94 (0.69–1.28)	0.95 (0.68–1.33)	1.35 (0.80–2.27)	1.58 (0.90–2.77)	2.28 (0.97–5.36)	2.45 (0.99–6.05)
	Q3/Q1	0.96 (0.71–1.31)	0.90 (0.65–1.27)	1.50 (0.90–2.50)	1.64 (0.93–2.87)	3.18 (1.41–7.19)*	3.85 (1.70–8.71)*
	Q4/Q1	1.09 (0.79–1.49)	1.00 (0.71–1.41)	1.35 (0.78–2.33)	1.47 (0.81–2.67)	3.24 (1.35–7.73)*	3.63 (1.51–8.73)*
ALT (IU/L)		1.00 (0.98–1.02)	1.00 (0.98–1.00)	1.01 (0.98–1.02)	1.00 (0.98–1.03)	1.01 (1.00–1.03)*	1.02 (1.01–1.04)*

^aMHO, Metabolic Healthy Obese.

^bMNHNO, Metabolic Non Healthy Non Obese.

^cMNHO, Metabolic Non Healthy Obese.

^dCrude model.

^eAdjusted for age, gender, physical activity, screen time, socioeconomic status, and living area.

*P < 0.05.

ALT, Alanine aminotransferase; CI, confidence interval; OR, odds ratio.

ALT Quartiles: Q1: ≤ 5 IU/L [n = 1,093], Q2: 6-7 IU/L [n = 983], Q3: 8-10 IU/L [n = 968], Q4: ≥ 11 IU/L [n = 799].

We did not detect any significant association between ALT level and different phenotypes of obesity regardless of MetS status (general/abdominal obesity). In contrast with our findings, some previous studies have documented the association of ALT with abdominal obesity (32, 33). In overweight children and adolescents, for each 5- cm increase in WC and every 1-point increase in BMI z- score, there was a 1.3-fold higher risk of having increased ALT levels (34). Compared with general obesity, abdominal obesity is more strongly correlated

with metabolic impairment (35). Besides, a study using data from an ultrasonography survey revealed that trunk fat was associated with increased serum ALT levels independently of anthropometric indices of general and abdominal obesity (36). Also, in children diagnosed with NAFLD, the strongest correlates to increased serum ALT levels across the spectrum of body weights were the abdominal skinfolds and the sum of the trunk skinfolds (37). In another study, multiple linear regression adjusted for several covariates found that obesity assessed by

abdominal height was a better correlate of ALT levels than BMI (38).

Limitations and Strengths

The main limitation of this study is the cross-sectional nature of the findings, which infer the causality of the associations. Moreover, we could not examine the pubertal status, and some of our findings might be influenced by puberty. The strengths of the study are the novelty in the pediatric population, the large sample size, and considering various phenotypes of obesity.

CONCLUSION

This large population-based study provides information on the association of ALT levels with different metabolic phenotypes of obesity in children and adolescents. MNHO group may have a higher mean ALT level compared to MHNO and MHO groups. Our findings although suggest that ALT level has not association with different phenotypes of obesity regardless of the MetS status (only abdominal obesity, only general obesity, and combined obesity).

REFERENCES

- Kelishadi R, Cook SR, Adibi A, Faghihimani Z, Ghatrehsamani S, Beighagi A, et al. Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. *Diabetol Metab Syndr.* (2009) 1:29. doi: 10.1186/1758-5996-1-29
- Motlagh ME, Qorbani M, Rafiemanzelat AM, Taheri M, Aminaee T, Shafiee G, et al. Prevalence of cardiometabolic risk factors in a nationally representative sample of Iranian children and adolescents: the CASPIAN-V Study. *J Cardiovasc Thorac Research.* (2018) 10:76. doi: 10.15171/jcvtr.2018.12
- Kunutsor SK, Seddoh D. Alanine aminotransferase and risk of the metabolic syndrome: a linear dose-response relationship. *PLoS One.* (2014) 9:e96068. doi: 10.1371/journal.pone.0096068
- Park JH, Kim SH, Park S, Park MJ. Alanine aminotransferase and metabolic syndrome in adolescents: the Korean National Health and Nutrition Examination Survey Study. *Pediatr Obes.* (2014) 9:411–8. doi: 10.1111/j.2047-6310.2013.00199.x
- Di Bonito P, Sanguigno E, Di Fraia T, Forziato C, Boccia G, Saitta F, et al. Association of elevated serum alanine aminotransferase with metabolic factors in obese children: sex-related analysis. *Metabolism.* (2009) 58:368–72. doi: 10.1016/j.metabol.2008.10.010
- Kelishadi R, Qorbani M, Heshmat R, Motamed-Gorji N, Motlagh ME, Ziaodini H. Association of alanine aminotransferase concentration with cardiometabolic risk factors in children and adolescents: the CASPIAN-V cross-sectional study. *Saõ Paulo Med J.* (2018) 136:511–9. doi: 10.1590/1516-3180.2018.0161161118
- Mohammadi F, Qorbani M, Kelishadi R, Baygi F, Ardalan G, Taslimi M, et al. Association of cardiometabolic risk factors and hepatic enzymes in a national sample of Iranian children and adolescents: the CASPIAN-III study. *J Pediatr Gastroenterol Nutr.* (2014) 58:463–8. doi: 10.1097/MPG.0000000000000246
- Aldhoon-Hainerová I, Hainer V, Zamrazilová H. Impact of dietary intake, lifestyle and biochemical factors on metabolic health in obese adolescents. *Nutr Metab Cardiovasc Dis.* (2017) 27:703–10. doi: 10.1016/j.numecd.2017.05.002
- Suárez-Ortegón MF, Echeverri I, Prats-Puig A, Bassols J, Carreras-Badosa G, López-Bermejo A, Fernández-Real JM. Iron status and metabolically

DATA AVAILABILITY STATEMENT

The data are obtained from a national surveillance program, so they cannot be accessed publicly; they can be provided after the approval of the steering committee of the project. Requests to access the datasets should be directed to mqorbani1379@yahoo.com.

AUTHOR CONTRIBUTIONS

RK and MQ participated in the sequence alignment and drafted the article. ZH participated in the study design, final revision, and edition. HR, GS, and RH participated in the sequence alignment and drafted the manuscript. MM and SD participated in the study design and interpretation. HZ and ZA participated in the data acquisition. MQ, SSD, and AM participated in the design of the study and performed statistical analysis. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors are thankful to the team working on this national project and all participants who cooperated with this study.

- unhealthy obesity in prepubertal children. *Obesity.* (2019) 27:636–44. doi: 10.1002/oby.22425
- Xie J, Zhang S, Yu X, Yang Y, Liu Z, Yuan G, et al. Association between liver enzymes with metabolically unhealthy obese phenotype. *Lipids Health Dis.* (2018) 17:198. doi: 10.1186/s12944-018-0847-9
- Kelishadi R, Ardalan G, Qorbani M, Ataie-Jafari A, Bahreynian M, Taslimi M, et al. Methodology and early findings of the fourth survey of childhood and adolescence surveillance and prevention of adult non-communicable disease in Iran: the CASPIAN-IV study. *Int J Prev Med.* (2013) 4:1451–60.
- Motlagh ME, Ziaodini H, Qorbani M, Taheri M, Aminaee T, Goodarzi A. Methodology and early findings of the fifth survey of childhood and adolescence surveillance and prevention of adult noncommunicable disease: the CASPIAN-V study. *Int J Prev Med.* (2017) 8:4. doi: 10.4103/2008-7802.198915
- WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. *Acta Paediatr Suppl.* (2006) 450:76–85. doi: 10.1111/j.1651-2227.2006.tb02378.x
- Kelishadi R, Majdzadeh R, Motlagh ME, Heshmat R, Aminaee T, Ardalan G, et al. Development and evaluation of a questionnaire for assessment of determinants of weight disorders among children and adolescents: the Caspian-IV study. *Int J Prev Med.* (2012) 3:699–705.
- American Academy of Pediatrics. National high blood pressure education program working group on high blood pressure in children and adolescents. *Pediatrics.* (2004) 114:555–76.
- Emamian MH, Zeraati H, Majdzadeh R, Shariati M, Hashemi H, Jafarzadehpour E, et al. Economic inequality in presenting near vision acuity in a middle-aged population: a Blinder–Oaxaca decomposition. *Br J Ophthalmol.* (2013) 97:1100–3. doi: 10.1136/bjophthalmol-2013-303249
- McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. *Clin Chim Acta.* (1987) 166:1–8. doi: 10.1016/0009-8981(87)90188-4
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* (1972) 18:499–502. doi: 10.1093/clinchem/18.6.499
- Ford ES, Ajani UA, Mokdad AH. The metabolic syndrome and concentrations of C-reactive protein among US youth. *Diabetes Care.* (2005) 28:878–81. doi: 10.2337/diacare.28.4.878

20. Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents. *The Lancet*. (2007) 369:2059–61. doi: 10.1016/S0140-6736(07)60958-1
21. Kelishadi R, Jamshidi F, Qorbani M, Motlagh ME, Heshmat R, Ardalan G, et al. Association of hypertriglyceridemic-waist phenotype with liver enzymes and cardiometabolic risk factors in adolescents: the CASPIAN-III study. *J Pediatr*. (2016) 92:512–20. doi: 10.1016/j.jpdp.2016.06.014
22. Kim HC, Choi KS, Jang YH, Shin HW, Kim DJ. Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. *Yonsei Med J*. (2006) 47:542–50. doi: 10.3349/ymj.2006.47.4.542
23. Tarantino G, Pizza G, Colao A, Pasanisi F, Conca P, Colicchio P, et al. Hepatic steatosis in overweight/obese females: new screening method for those at risk. *World J Gastroenterol*. (2009) 15:5693. doi: 10.3748/wjg.15.5693
24. Roberson LL, Aneni EC, Maziak W, Agatston A, Feldman T, Rouseff M, et al. Beyond BMI: the “Metabolically healthy obese” phenotype and its association with clinical/subclinical cardiovascular disease and all-cause mortality—a systematic review. *BMC Public Health*. (2014) 14:14. doi: 10.1186/1471-2458-14-14
25. D’Adamo E, Cali AM, Weiss R, Santoro N, Pierpont B, Northrup V, et al. Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents. *Diabetes Care*. (2010) 33:1817–22. doi: 10.2337/dc10-0284
26. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. *Arch Intern Med*. (2008) 168:1609–16. doi: 10.1001/archinte.168.15.1609
27. Franco LP, Morais CC, Cominetti C. Normal-weight obesity syndrome: diagnosis, prevalence, and clinical implications. *Nutr Rev*. (2016) 74:558–70. doi: 10.1093/nutrit/nuw019
28. Olafsdottir AS, Torfadottir JE, Arngrimsson SA. Health behavior and metabolic risk factors associated with normal weight obesity in adolescents. *PLoS ONE*. (2016) 11:e0161451. doi: 10.1371/journal.pone.0161451
29. De Lorenzo A, da Cruz Lamas C, Lessa R, Moreira AS. “Metabolically Healthy” obesity: fact or threat? *Curr Diabetes Rev*. (2018) 14: 405–10. doi: 10.2174/1573399813666170502105859
30. Kelishadi R, Hashemipour M, Sarrafzadegan N, Mohammadifard N, Alikhany H, Beizaei M, et al. Effects of a lifestyle modification trial among phenotypically obese metabolically normal and phenotypically obese metabolically abnormal adolescents in comparison with phenotypically normal metabolically obese adolescents. *Matern Child Nutr*. (2010) 6:275–86. doi: 10.1111/j.1740-8709.2009.00207.x
31. Lee SH, Han K, Yang HK, Kim HS, Cho JH, Kwon HS, et al. A novel criterion for identifying metabolically obese but normal weight individuals using the product of triglycerides and glucose. *Nutr Diabetes*. (2015) 5:e149. doi: 10.1038/ntud.2014.46
32. Ahn MB, Bae WR, Do Han K, Cho WK, Cho KS, Park SH, et al. Association between serum alanine aminotransferase level and obesity indices in Korean adolescents. *Korean J Pediatr*. (2015) 58:165. doi: 10.3345/kjp.2015.58.5.165
33. Stranges S, Dorn JM, Muti P, Freudenheim JL, Farinaro E, Russell M, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. *Hepatology*. (2004) 39:754–63. doi: 10.1002/hep.20149
34. Oliveira AC, Oliveira AM, Almeida MS, Silva AM, Adan L, Ladeia AM. Alanine aminotransferase and high sensitivity C-reactive protein: correlates of cardiovascular risk factors in youth. *J Pediatr*. (2008) 152:337–42. doi: 10.1016/j.jpeds.2007.07.013
35. Kelishadi R, Mirmoghtadaee P, Najafi H, Keikha M. Systematic review on the association of abdominal obesity in children and adolescents with cardiometabolic risk factors. *J Res Med Sci*. (2015) 20:294–307.
36. Ruhl CE, Everhart JE. Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States. *Gastroenterology*. (2010) 138:1346–56. doi: 10.1053/j.gastro.2009.12.053
37. Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease. *Nutr Clin Pract*. (2013) 28:101–11. doi: 10.1177/0884533612454884
38. Kim J, Jo I. Relationship between body mass index and alanine aminotransferase concentration in non-diabetic Korean adults. *Eur J Clin Nutr*. (2010) 64:169–75. doi: 10.1038/ejcn.2009.131

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Kelishadi, Hemati, Qorbani, Motlagh, Djalalinia, Ahadi, Shafiee, Mahdavi Gorabi, Rastad, Ziaodini, Daniali and Heshmat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.